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1. INTRODUCTION {#cas13610-sec-0001}
===============

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers known to medicine. The 5‐year survival period of patients with PDAC is approximately 5%.[1](#cas13610-bib-0001){ref-type="ref"} At first diagnosis, most patients with PDAC have local invasion or distant metastasis, and only about 15% of patients are candidates for surgical resection.[2](#cas13610-bib-0002){ref-type="ref"} Currently developed combination chemotherapies have a limited therapeutic impact on patients with advanced stage disease.[3](#cas13610-bib-0003){ref-type="ref"} Therefore, improved understanding of the underlying pathological mechanisms could lead to new therapeutic approaches for this disease.

In recent years, microRNA (miRNA) has received considerable attention as a crucial molecule that controls the expression of protein‐coding or non‐coding genes. Regulation is achieved by translational repression or mRNA cleavage in a sequence‐specific method.[4](#cas13610-bib-0004){ref-type="ref"} Currently developed bioinformatics approaches indicate that 1 miRNA can regulate thousands of mRNAs and, conversely, most protein‐coding genes in the genome are under the control of miRNAs.[5](#cas13610-bib-0005){ref-type="ref"} Therefore, aberrantly expressed miRNAs can disturb entire networks of mRNAs and proteins.

Identification of dysregulated miRNAs in cancer cells is an important first step in elucidating aberrantly expressed genes and proteins in cancer. Based on this background, our groups have been comprehensively studying specimens of several cancers by genome‐wide miRNA expression analyses.[6](#cas13610-bib-0006){ref-type="ref"}, [7](#cas13610-bib-0007){ref-type="ref"} Analyses of miRNA expression signatures of PDAC clinical specimens by RNA sequencing showed that some passenger strands of miRNAs (eg, *miR‐216a‐3p*,*miR‐216b‐3p*,*miR‐148a‐5p*,*miR‐129‐1‐3p* and *miR‐129‐2‐3p*) were significantly downregulated in cancer tissues.[8](#cas13610-bib-0008){ref-type="ref"} In miRNA biogenesis, it is generally believed that 1 strand of the mature duplex miRNA (the guide strand) is incorporated into the miRNA‐induced silencing complex (RISC) and its control target genes by RNA degradation and translational repression.[9](#cas13610-bib-0009){ref-type="ref"} In contrast to the guide strand, the passenger strand of miRNA was previously thought to be degraded and to have no function.[10](#cas13610-bib-0010){ref-type="ref"}, [11](#cas13610-bib-0011){ref-type="ref"}

Contrary to established beliefs, our recent studies indicated that several passenger strands of miRNAs acted as antitumor miRNAs in several cancers.[12](#cas13610-bib-0012){ref-type="ref"}, [13](#cas13610-bib-0013){ref-type="ref"} For example, *miR‐145‐3p* (passenger strand) was significantly downregulated in castration‐resistant prostate cancer and restoration of *miR‐145‐3p* inhibited cancer cell migration and invasion through targeting of *MELK*,*NCAPG*,*BUB1*, and *CDK1*.[14](#cas13610-bib-0014){ref-type="ref"} Similarly, antitumor functions have also been shown in bladder cancer and lung cancer.[15](#cas13610-bib-0015){ref-type="ref"}, [16](#cas13610-bib-0016){ref-type="ref"} Realization that the passenger strand of miRNA is involved in the regulation of RNA networks will improve our understanding of cancer cell development and tumor progression.

In the present study, our goal was to identify novel therapeutic targets in lethal PDAC. Based on our original miRNA expression signature of PDAC, we focused on pre‐*miR‐148a* (*miR‐148a‐5p* \[passenger strand\] and *miR‐148a‐3p* \[guide strand\]) and investigated the functional significance of these miRNAs and their regulatory RNA networks in PDAC cells. Elucidation of molecular networks modulated by novel antitumor miRNAs in PDAC cells may provide new insights into the pathological mechanisms underlying the disease.

2. MATERIALS AND METHODS {#cas13610-sec-0002}
========================

2.1. Clinical specimens and cell lines {#cas13610-sec-0003}
--------------------------------------

Clinical tissue specimens (n = 30) were obtained from patients with PDAC who underwent curative surgical resection at Kagoshima University Hospital between 1997 and 2016. Normal pancreatic tissue specimens (n = 18) were obtained from non‐cancerous tumor‐adjacent tissues. Each surgical specimen was histologically characterized according to the TNM classification system.[17](#cas13610-bib-0017){ref-type="ref"} All patients in this study provided informed consent and the study protocol was approved by the Institutional Review Board of Kagoshima University. Quantitative real‐time PCR (qRT‐PCR) of clinical samples was carried out by extracted total RNA from frozen specimens, immunohistochemistry was performed by PDAC tissues from formalin‐fixed paraffin‐embedded. Two human PDAC cell lines (PANC‐1 and SW1990) were used in this study as described previously.[8](#cas13610-bib-0008){ref-type="ref"}, [18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}

2.2. Quantitative real‐time PCR {#cas13610-sec-0004}
-------------------------------

Protocols for total RNA extraction from clinical specimens and cell lines were described in previous studies. The procedure for quantification of miRNAs and mRNAs was described earlier.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}, [20](#cas13610-bib-0020){ref-type="ref"}, [21](#cas13610-bib-0021){ref-type="ref"} TaqMan qRT‐PCR probes and primers were obtained from Thermo Fisher Scientific (Waltham, MA, USA) as follows: *miR‐148a‐5p* (product ID: 002134); *miR‐148a‐3p* (product ID: 000470); *PHLDA2*(product ID: Hs00169368_m1); *LPCAT2* (product ID: Hs01044164_m1); *AP1S3* (product ID: Hs00950999_m1); *SMS* (product ID: Hs01924834_u1); *ENDOD1* (product ID: Hs00826684_m1); *UHMK1* (product ID: Hs00332674_m1). Human *GUSB* (product ID: Hs99999908_m1), *RNU48* (product ID: 001006), *miR‐26a* (product ID: 000405), *miR‐21* (product ID: 000397) were used as internal controls.

2.3. Transfection of miRNA mimic, siRNA and cDNA cloning into PDAC cell lines {#cas13610-sec-0005}
-----------------------------------------------------------------------------

The procedure for miRNA, siRNA and cDNA plasmid transfection into cancer cells was described previously.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}, [20](#cas13610-bib-0020){ref-type="ref"}, [21](#cas13610-bib-0021){ref-type="ref"} Pre‐miR™ miRNA precursors for *miR‐148a‐5p* (product ID: PM 12683), *miR‐148a‐3p* (product ID: PM 10263), negative control miRNA (product ID: AM 17010), 2 *PHLDA2* siRNAs (product IDs: HSS144353 and HSS144354) and negative control siRNA (product ID: D‐001810‐10) were purchased from Thermo Fisher. A Flexi HaloTag cDNA clone of *PHLDA2* (Vector: pFN21A, Product ID: FHC02241) was purchased from Kazusa Genome Technologies (Chiba, Japan). Transfection efficiencies of miRNA and siRNA in cell lines were calculated as described.[22](#cas13610-bib-0022){ref-type="ref"}

2.4. Cell proliferation, migration and invasion assays {#cas13610-sec-0006}
------------------------------------------------------

Protocols for functional assays (cell proliferation, migration and invasion) were described previously.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}, [20](#cas13610-bib-0020){ref-type="ref"}, [21](#cas13610-bib-0021){ref-type="ref"}

2.5. Argonaute 2(Ago2)‐bound miRNA isolation by immunoprecipitation {#cas13610-sec-0007}
-------------------------------------------------------------------

PANC‐1 and SW1990 cells growing on 6‐well plates were transfected with 10 nmol/L pre‐*miR‐148a*. After reverse transfection, immunoprecipitation was carried out using a microRNA Isolation kit, Human Ago2 (Wako, Osaka, Japan). The procedure was as described previously.[13](#cas13610-bib-0013){ref-type="ref"}, [14](#cas13610-bib-0014){ref-type="ref"}

2.6. Western blot analyses and immunohistochemistry {#cas13610-sec-0008}
---------------------------------------------------

Antibodies against PHLDA2 (product ID: ab99209; Abcam, Tokyo, Japan), poly (ADP‐ribose) polymerase (PARP) antibody (product ID: 9542; Cell Signaling Technology, Danvers, MA, USA) and GAPDH (product ID: SAF6698; Wako) were used in this study. The procedures for western blotting and tissue immunohistochemistry were as described previously.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}, [23](#cas13610-bib-0023){ref-type="ref"}

2.7. Genome‐wide gene expression and in silico analyses {#cas13610-sec-0009}
-------------------------------------------------------

To identify genes targeted by *miR‐148a‐5p* and *miR‐148a‐3p*, we used a combination of in silico analyses and genome‐wide gene expression analyses as described previously.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}, [23](#cas13610-bib-0023){ref-type="ref"} Expression data by microarray analyses were deposited into the Gene Expression Omnibus (GEO) database (accession numbers [GSE15471](GSE15471), [GSE93290](GSE93290)).

2.8. The Cancer Genome Atlas (TCGA) database analysis of PDAC specimens {#cas13610-sec-0010}
-----------------------------------------------------------------------

The clinical significance of the expression of miRNAs or target genes and relation to PDAC pathogenesis were determined with the OncoLnc database (<http://www.oncolnc.org>).[18](#cas13610-bib-0018){ref-type="ref"}, [24](#cas13610-bib-0024){ref-type="ref"}, [25](#cas13610-bib-0025){ref-type="ref"} Clinical information on 174 PDAC samples was obtained from National Cancer Institute GDC Data Portal (<https://portal.gdc.cancer.gov>) and cBioPortal (<http://www.cbioportal.org>). TNM stage, T stage, N stage and M stage on TCGA pathological database were evaluated by The American Joint Committee on Cancer (AJCC). Disease‐free survival (DFS) within 3 years and recurrence were analyzed in 113 PDAC samples where data were disclosed.

2.9. Plasmid construction and dual‐luciferase reporter assay {#cas13610-sec-0011}
------------------------------------------------------------

The vector used for dual‐luciferase reporter assay was psiCHECK‐2 vector (C8021; Promega, Madison, WI, USA). The cloned sequences are listed in Figure [S1](#cas13610-sup-0001){ref-type="supplementary-material"}. The procedure for dual‐luciferase reporter assay was described previously.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}, [20](#cas13610-bib-0020){ref-type="ref"}, [21](#cas13610-bib-0021){ref-type="ref"}

2.10. Identification of downstream targets regulated by *PHLDA2* in PDAC {#cas13610-sec-0012}
------------------------------------------------------------------------

Genome‐wide microarray analysis was applied for identification of *PHLDA2* downstream targets. Expression data were deposited in the GEO database ([GSE106791](GSE106791)). Genes downregulated by *PHLDA2* were assessed for PDAC prognosis using TCGA database.

2.11. Statistical analysis {#cas13610-sec-0013}
--------------------------

Relationships between 2 groups and expression values obtained by qRT‐PCR were analyzed using the Mann‐Whitney *U* test. Correlation between expression of *miR‐148a‐5p, miR‐148a‐3p* and *PHLDA2* was evaluated using Spearman\'s rank test. Relationships among more than 3 variables and numerical values were analyzed using the Bonferroni‐adjusted Mann‐Whitney *U* test. Overall survival (OS) and DFS after surgery were gauged using Kaplan--Meier curves. Patients were divided into 2 groups based on high and low gene expression around the median, and differences in survival were estimated using the log‐rank test. We used Expert StatView software (version 5.0; SAS Institute Inc., Cary, NC, USA) for these analyses.[18](#cas13610-bib-0018){ref-type="ref"}, [19](#cas13610-bib-0019){ref-type="ref"}

3. RESULTS {#cas13610-sec-0014}
==========

3.1. Expression levels of *miR‐148a‐5p* and *miR‐148a‐3p* in PDAC specimens and cell lines {#cas13610-sec-0015}
------------------------------------------------------------------------------------------

Expression levels of *miR‐148a‐5p and miR‐148a‐3p* in PDAC tissues (n = 30), normal pancreatic tissues (n = 18) and 2 PDAC cell lines (PANC‐1 and SW1990) were evaluated. Characteristics of the clinical samples are summarized in Tables [1](#cas13610-tbl-0001){ref-type="table-wrap"}, [2](#cas13610-tbl-0002){ref-type="table-wrap"} . Expression levels of *miR‐148a‐5p* and *miR‐148a‐3p* were significantly lower in tumor tissues compared with normal pancreatic tissues (*P *\<* *.0001 and *P *=* *.0004, respectively, Figure [1](#cas13610-fig-0001){ref-type="fig"}A). Spearman\'s rank test showed positive correlations between the expression of *miR‐148a‐5p* and *miR‐148a‐3p* (*R *=* *.669 and *P *\<* *.0001; Figure [1](#cas13610-fig-0001){ref-type="fig"}B). However, there were no significant relationships between any of the clinical features (ie, neoadjuvant chemotherapy, metastasis or recurrence) and the expression of *miR‐148a‐5p* and *miR‐148a‐3p* (data not shown).

###### 

Characteristics of patients in the present study: pancreatic ductal adenocarcinoma

  ------------------------------ --------------
  Total no.                      30
  Average age (range) years      65.4 (42‐85)
  Gender (%)                     
  Male                           14 (46.7)
  Female                         16 (53.3)
  T category (%)                 
  pTis                           1 (3.3)
  pT1                            10 (33.3)
  pT2                            13 (43.3)
  pT3                            4 (13.3)
  pT4                            2 (6.7)
  N category (%)                 
  0                              17 (56.7)
  1                              13 (43.3)
  M category (%)                 
  0                              28 (93.3)
  1                              2 (6.7)
  Neoadjuvant chemotherapy (%)   
  (−)                            12 (40.0)
  (+)                            18 (60.0)
  Recurrence (%)                 
  (−)                            13 (43.3)
  (+)                            17 (56.7)
  ------------------------------ --------------

John Wiley & Sons, Ltd

###### 

Characteristics of patients in the present study: normal pancreatic tissue

  --------------------------- --------------
  Total no.                   18
  Average age (range) years   65.9 (42‐85)
  Gender (%)                  
  Male                        7 (38.9)
  Female                      11 (61.1)
  --------------------------- --------------

John Wiley & Sons, Ltd

![Antitumor functions of *pre‐miR‐148a* in pancreatic ductal adenocarcinoma (PDAC) cell lines (PANC‐1 and SW1990). A, Expression levels of *miR‐148a‐5p and miR‐148a‐3p* in PDAC clinical specimens and cell lines were determined by qRT‐PCR. Data were normalized to *RNU48* expression. B, Expression levels of *miR‐148a‐3p* and *miR‐148‐5p* were positively correlated (*R *=* *.699, *P *\<* *.0001). C, Cell proliferation was determined by XTT assays 72 h after transfection with 10 nmol/L *miR‐148a‐5p* or *miR‐148a‐3p*, \**P *\<* *.0001. D, Cell invasion activity was determined using Matrigel invasion assays, \**P *\<* *.0001. E, Cell migration activity was determined by migration assays, \**P *\<* *.0001](CAS-109-2013-g001){#cas13610-fig-0001}

3.2. Both *miR‐148a‐5p* and *miR‐148a‐3p* bound to Ago2 {#cas13610-sec-0016}
-------------------------------------------------------

To investigate whether the *miR‐148a‐5p* (passenger strand) is incorporated into RISC, we carried out immunoprecipitation with antibodies targeting Ago2. After transfection with *miR‐148a‐5p* or *miR‐148a‐3p*, Ago2‐bound miRNAs were isolated, and qRT‐PCR was carried out to determine whether *miR‐148a‐5p* or *miR‐148a‐3p* was bound to Ago2 (Figure [S2](#cas13610-sup-0002){ref-type="supplementary-material"}A,B).

After transfection of PANC‐1 and SW1990 cells with *miR‐148a‐5p* and immunoprecipitation by anti‐Ago2 antibodies, *miR‐148a‐5p* levels were significantly higher than those of mock or control transfected cells and those of *miR‐148a‐3p*‐transfected cells (Figure [S2](#cas13610-sup-0002){ref-type="supplementary-material"}C, middle). Similarly, after *miR‐148a‐3p* transfection, *miR‐148a‐3p* levels were significantly higher than those of mock or control transfected cells and those of *miR‐148a‐5p* transfected cells (Figure [S2](#cas13610-sup-0002){ref-type="supplementary-material"}C, lower). This suggests that *miR‐148a‐5p* was incorporated into RISC when *miR‐148a‐5p* was transfected, *miR‐148a‐3p* was incorporated into RISC when *miR‐148a‐3p* was transfected, and pre*‐miR‐148a* acts on cell lines separately to *miR‐148a‐5p* and *miR‐148a‐3p*. *miR‐21* was used as an internal control of microRNA level expression between each sample (Figure [S2](#cas13610-sup-0002){ref-type="supplementary-material"}C, upper).

3.3. DNA methylation and *miR‐148a* expression levels {#cas13610-sec-0017}
-----------------------------------------------------

Expression levels of *miR‐148a‐5p* and *miR‐148a‐3p* were markedly lower in the 2 cell lines (Figure [1](#cas13610-fig-0001){ref-type="fig"}A). To elucidate the molecular mechanisms underlying the low expression of *miR‐148a‐5p and miR‐148a‐3p* in PDAC cells, the PANC‐1 cell line was treated with a demethylating agent (5‐aza‐2′‐deoxycytidine \[5‐aza‐dC\]). Expression levels of *miR‐148a‐5p* and *miR‐148a‐3p* in PANC‐1 cells were significantly elevated by 5‐aza‐dC treatment (Figure [S3](#cas13610-sup-0003){ref-type="supplementary-material"}B). These data suggested that DNA methylation might cause silencing of *miR‐148a‐5p and miR‐148a‐3p* in PDAC cells.

3.4. Effects of *miR‐148a‐5p* and *miR‐148a‐3p* expression on cell growth, apoptosis, migration and invasiveness of PDAC cell lines {#cas13610-sec-0018}
-----------------------------------------------------------------------------------------------------------------------------------

Gain‐of‐function studies were carried out to investigate the functional roles of *miR‐148a‐5p* and *miR‐148a‐3p*. XTT assays showed significant inhibition of cell proliferation in PANC‐1 or in SW1990 cells transfected with *miR‐148a‐5p* or *miR‐148a‐3p* in comparison with mock or control transfectants (*P *\<* *.0001, Figure [1](#cas13610-fig-0001){ref-type="fig"}C). Apoptotic cell numbers (early apoptotic and late apoptotic cells) were significantly larger in *miR‐148a‐5p* or *miR‐145‐3p* transfectants than in mock or negative control transfectants (Figure [S4](#cas13610-sup-0004){ref-type="supplementary-material"}A,B). Western blot analyses showed that cleaved PARP expression was significantly increased in *miR‐148a‐5p* or *miR‐148a‐3p* transfectants compared with mock or negative control transfectants (Figure [S4](#cas13610-sup-0004){ref-type="supplementary-material"}C). In vitro assays showed that migration and invasion were significantly inhibited in *miR‐148a‐5p* or *miR‐148a‐3p* transfectants compared with mock or miR‐control transfectants (each *P *\<* *.0001, Figure [1](#cas13610-fig-0001){ref-type="fig"}D,E). These results suggested that pre*‐miR‐148a* could have an antitumor function in PDAC cells.

3.5. Identification of candidate genes regulated by *miR‐148a‐5p* and *miR‐148‐3p* in PDAC cells {#cas13610-sec-0019}
------------------------------------------------------------------------------------------------

Next, we attempted to identify target genes coordinately regulated by *miR‐148‐5p* and *miR‐148a‐3p*. The strategies for narrowing down the genes targeted by *miR‐148a‐5p and miR‐148a‐3p* are shown in Figure [2](#cas13610-fig-0002){ref-type="fig"}. We carried out a combination of in silico analysis, GEO analysis and genome‐wide gene expression analysis using PDAC cell lines (PANC‐1 and SW1990) transfected with *miR‐148a‐5p* or *miR‐148a‐3p* (GEO accession number [GSE93290](GSE93290)).

![Strategy for analysis of *pre‐miR‐148a* candidate target genes. Strategy for identification of putative candidate genes regulated by (A) *miR‐148a‐5p* and (B) *miR‐148a‐3p* in pancreatic ductal adenocarcinoma (PDAC) cells. Approach to identifying *miR‐148a‐5p* and *miR‐148a‐3p* target genes. We used in silico analysis of genome‐wide gene expression, TargetScan and Gene Expression Omnibus (GEO) database analysis of *miR‐148a‐5p* and *miR‐148a‐3p* transfected PANC‐1 and SW1990 cells](CAS-109-2013-g002){#cas13610-fig-0002}

In PANC‐1 and SW1990 cells transfected with *miR‐148a‐5p*, a total of 1033 and 176 genes, respectively, were downregulated. Furthermore, the TargetScan database showed that 414 and 90 of those genes, respectively, had putative target sites for *miR‐148a‐5p* in their 3′‐UTR. We found that there were 68 common genes targeted in both cell lines. Last, gene expression data showed that 6 of those genes were upregulated (fold‐change log~2~ \> 1.0) in cancer tissues according to GEO database analyses (GEO accession number [GSE15471](GSE15471)).

In *miR‐148a‐3p* transfectants, a total of 629 and 250 genes, respectively, were downregulated in PANC‐1 and SW1990. Furthermore, the TargetScan database showed that 186 and 121 genes, respectively, had putative target sites for *miR‐148a‐3p* in their 3′‐UTR. We found that there were 59 common genes targeted in both cell lines. Last, 9 genes were upregulated (fold‐change log~2~ \> 1.0) in cancer tissues by GEO database analyses (GEO accession number [GSE15471](GSE15471)).

We also checked the clinical significance of 6 genes targeted by *miR‐148a‐5p* (Table [3](#cas13610-tbl-0003){ref-type="table-wrap"}) and 9 genes targeted by *miR‐148a‐3p* (Table [4](#cas13610-tbl-0004){ref-type="table-wrap"}). Kaplan‐Meier survival curves showed that high expression of all 6 of the genes was associated with poor prognoses in PDAC in the TCGA database. Target genes of *miR‐148a‐5p* included *PHLDA2*,*LPCAT2* and *AP1S3,* whereas target genes of *miR‐148a‐3p* included *SMS*,*ENDOD1* and *UHMK1* where mRNA expression levels were significantly upregulated. On TCGA database, patients showing elevated expression of all 6 target genes had a significantly poorer overall survival by Kaplan‐Meier analysis (Figure [3](#cas13610-fig-0003){ref-type="fig"}). Furthermore, high expression of target genes tended to indicate recurrence and DFS was shorter (Figure [3](#cas13610-fig-0003){ref-type="fig"}). Next, we validated PDAC and normal pancreatic tissue in our specimens, and carried out qRT‐PCR analysis of each target gene\'s mRNA expression level. *PHLDA2*,*LPCAT2*,*AP1S3*,*ENDOD1* and *UHMK1* showed significantly high expression in PDAC (Figure [4](#cas13610-fig-0004){ref-type="fig"}, left panels). In addition, we carried out qRT‐PCR analysis of each target gene\'s mRNA expression level using RNA from PANC‐1 and SW1990 cells that had been transfected with *miR‐148a‐5p* mimic or *miR‐148a‐3p* mimic. The data showed that each target gene\'s expression was downregulated (Figure [4](#cas13610-fig-0004){ref-type="fig"}, right panels).

###### 

Candidate target genes regulated by *miR‐148a‐5p*

  Entrez gene ID   Gene symbol   Gene name                                             miR‐148a‐5p   Expression in miR‐148a‐5p transfectants FC(log~2~)   GEO data ([GSE15471](GSE15471))   [a](#cas13610-note-0002){ref-type="fn"}TCGA_OncoLnc *P*‐value   
  ---------------- ------------- ----------------------------------------------------- ------------- ---------------------------------------------------- --------------------------------- --------------------------------------------------------------- -------
  7262             *PHLDA2*      Pleckstrin homology‐like domain, family A, member 2   1             −2.343                                               −1.560                            2.847                                                           .0361
  11167            *FSTL1*       Follistatin‐like 1                                    1             −1.307                                               −1.433                            1.841                                                           .2790
  54947            *LPCAT2*      Lysophosphatidylcholine acyltransferase 2             4             −1.385                                               −1.458                            1.474                                                           .0039
  23531            *MMD*         Monocyte to macrophage differentiation‐associated     1             −1.816                                               −1.030                            1.414                                                           .6490
  1808             *DPYSL2*      Dihydropyrimidinase‐like 2                            1             −2.039                                               −2.620                            1.288                                                           .9210
  130340           *AP1S3*       Adaptor‐related protein complex 1, sigma 3 subunit    2             −1.117                                               −1.313                            1.166                                                           .0041

GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.

Kaplan‐Meier analysis log‐rank *P*‐value \<.05, poor prognosis with a high expression.

John Wiley & Sons, Ltd

###### 

Candidate target genes regulated by *miR‐148a‐3p*

  Entrez gene ID   Gene symbol   Gene name                                      miR‐148a‐3p   Expression in miR‐148a‐5p transfectants FC(log~2~)   GEO data ([GSE15471](GSE15471))   [a](#cas13610-note-0004){ref-type="fn"}TCGA_OncoLnc *P*‐value   
  ---------------- ------------- ---------------------------------------------- ------------- ---------------------------------------------------- --------------------------------- --------------------------------------------------------------- -------
  3106             *HLA‐B*       Major histocompatibility complex, class I, B   1             −1.333                                               −1.418                            1.411                                                           .7440
  8829             *NRP1*        Neuropilin 1                                   2             −2.024                                               −1.411                            1.302                                                           .9850
  6611             *SMS*         Spermine synthase                              1             −1.447                                               −1.650                            1.263                                                           .0032
  54492            *NEURL1B*     Neuralized homolog 1B (Drosophila)             1             −1.438                                               −1.528                            1.236                                                           .1540
  3134             *HLA‐F*       Major histocompatibility complex, class I, F   1             −1.401                                               −1.176                            1.216                                                           .2220
  3105             *HLA‐A*       Major histocompatibility complex, class I, A   2             −1.544                                               −1.713                            1.187                                                           .7310
  23052            *ENDOD1*      Endonuclease domain containing 1               2             −1.135                                               −1.500                            1.177                                                           .0003
  5476             *CTSA*        Cathepsin A                                    1             −1.747                                               −1.704                            1.078                                                           .2780
  127933           *UHMK1*       U2AF homology motif (UHM) kinase 1             3             −1.583                                               −1.085                            1.029                                                           .0131

GEO, Gene Expression Omnibus; TCGA, The Cancer Genome Atlas.

Kaplan‐Meier analysis log‐rank *P*‐value \<.05, poor prognosis with a high expression.

John Wiley & Sons, Ltd

![Overall survival, disease‐free survival and recurrence of target genes by *miR‐148a‐5p* and *miR‐148a‐3p* on The Cancer Genome Atlas (TCGA) database. A, Three candidate genes modulated by *miR‐148a‐5p* (*PHLDA2, LPCAT2, AP1S3*). Kaplan‐Meier analysis and the prognostic factors for pancreatic ductal adenocarcinoma (PDAC) are shown, \**P *\<* *.05. B, Three candidate genes modulated by *miR‐148a‐3p* (*SMS,ENDOD1, UHMK1*). Kaplan‐Meier analysis and the prognostic factors for PDAC are shown, \**P *\<* *.05](CAS-109-2013-g003){#cas13610-fig-0003}

![Messenger RNA expression of target genes of *miR‐148a‐5p* and *miR‐148a‐3p* on clinical sample and directly regulation of mRNA expression by *miR‐148a‐5p* and *miR‐148a‐3p* transfectants in pancreatic ductal adenocarcinoma (PDAC) cell lines. A, Expression levels of *miR‐148a‐5p* target genes (*PHLDA2, LPCAT2, AP1S3*) in PDAC clinical specimens and cell lines were determined by qRT‐PCR. *GUSB* was used as an internal control, data were normalized to *GUSB* expression (left), \**P *\<* *.05. Gene expression was directly downregulated by transfection of *miR‐148a‐5p* mimic (right), \**P *\<* *.0001. B, Expression levels of *miR‐148a‐3p* target genes (*SMS*,*ENDOD1*,*UHMK1*) in PDAC clinical specimens and cell lines were determined by qRT‐PCR. *GUSB* was used as an internal control, data were normalized to *GUSB* expression (left), \**P *\<* *.05. Gene expression was directly downregulated by transfection of *miR‐148a‐3p* mimic (right), \**P *\<* *.0001](CAS-109-2013-g004){#cas13610-fig-0004}

In the present study, we focused on the Pleckstrin Homology Like Domain Family A Member 2 (*PHLDA2*) because *miR‐148a‐5p* (passenger strand) achieved the greatest degree of downregulation (Figure [4](#cas13610-fig-0004){ref-type="fig"}A, upper, right).

3.6. Direct regulation of *PHLDA2* by *miR‐148a‐5p* in PDAC cells {#cas13610-sec-0020}
-----------------------------------------------------------------

Negative correlations were detected between *miR‐148a‐5p* and *PHLDA2* expression (*R *=* *−.495, *P *=* *.0007, Figure [5](#cas13610-fig-0005){ref-type="fig"}A). Both *PHLDA2* mRNA and PHLDA2 protein levels were markedly reduced in *miR‐148a‐5p* transfectant cells (Figure [4](#cas13610-fig-0004){ref-type="fig"}A, upper, right, Figure [5](#cas13610-fig-0005){ref-type="fig"}B).

![Direct regulation of *PHLDA2* by *miR‐148a‐5p* in pancreatic ductal adenocarcinoma (PDAC) cell lines and immunohistochemical staining of PHLDA2 protein in PDAC clinical specimens. A, Expression levels of *PHLDA2* and *miR‐148a‐5p* were negatively correlated. B, PHLDA2 protein expression in PDAC cell lines was evaluated by western blot analyses 96 h after transfection with *miR‐148a‐5p*. GAPDH was used as a loading control. C, *miR‐148a‐5p* binding sites in the 3′‐UTR of *PHLDA2* mRNA. Dual luciferase reporter assays using vectors encoding the putative *miR‐148a‐5p* (positions 77‐83) target site of the *PHLDA2* 3′‐UTR for both wild‐type and deleted regions. Normalized data were calculated as ratios of *Renilla*/firefly luciferase activities, \**P *\<* *.05. D, Immunohistochemical staining of *PHLDA2* in PDAC specimens. All differentiated types of PDAC (well, moderate and poor) showed strong intracellular immunoreactivity (left panel, H&S staining; right panel, *PHLDA2* staining; original magnification, ×200; scale bars, 200 μm)](CAS-109-2013-g005){#cas13610-fig-0005}

The putative target site in the 3′‐UTR of *PHLDA2* is shown in Figure [S1](#cas13610-sup-0001){ref-type="supplementary-material"}. Luminescence intensity was significantly reduced by cotransfection with *miR‐148a‐5p* and the vector carrying the wild‐type 3′‐UTR (position 77‐83), whereas transfection with the deletion vector (deletion of binding site) blocked the decrease in luminescence (*P *\<* *.0001, Figure [5](#cas13610-fig-0005){ref-type="fig"}C).

A total of 30 specimens was evaluated by immunohistochemical staining. All tumors were of differentiated adenocarcinoma type (well, moderate and poor) and showed strong intracellular immunoreactivity. However, normal pancreatic tissue was not stained (Figure [5](#cas13610-fig-0005){ref-type="fig"}D).

3.7. Effects of silencing *PHLDA2* on PDAC cell lines {#cas13610-sec-0021}
-----------------------------------------------------

To investigate the oncogenic functions of *PHLDA2* in PDAC cells by using si‐*PHLDA2*, we evaluated the knockdown efficiency of si‐*PHLDA2* transfection in PDAC cell lines. In this assay, we used 2 types of si‐*PHLDA2* (si‐*PHLDA2‐1* and si‐*PHLDA2‐2*). Both siRNAs effectively downregulated *PHLDA2* mRNA/PHLDA2 protein expression in both cell lines (*P *\<* *.0001, Figure [6](#cas13610-fig-0006){ref-type="fig"}A,B).

![*PHLDA2* mRNA and PHLDA2 protein expression after *si‐PHLDA2* transfection and the effects of *PHLDA2* knockdown in pancreatic ductal adenocarcinoma (PDAC) cell lines. A, *PHLDA2* mRNA expression in PDAC cell lines was evaluated by qRT‐PCR 72 h after transfection with *si‐PHLDA2*‐1 or *si‐PHLDA2*‐2. *GUSB* was used as an internal control, data were normalized to *GUSB* expression. B, PHLDA2 protein expression in PDAC cell lines was evaluated by western blot analysis 96 h after transfection with *si‐PHLDA2‐1* and *si‐PHLDA2‐2*. GAPDH was used as a loading control. C, Cell proliferation was determined with XTT assays 72 h after transfection with 10 nmol/L *si‐PHLDA2*‐1 or *si‐PHLDA2*‐2, \**P *\<* *.0001. D, Cell invasion activity was determined using Matrigel invasion assays, \**P *\<* *.0001. E, Cell migration activity was determined by migration assays, \**P *\<* *.0001](CAS-109-2013-g006){#cas13610-fig-0006}

Cancer cell proliferation, migration and invasion abilities were inhibited in si‐*PHLDA2* transfectants compared with mock‐ or siRNA‐control‐transfected cells (Figure [6](#cas13610-fig-0006){ref-type="fig"}C‐E). In the apoptosis assays, si‐*PHLDA2*‐1 and si‐*PHLDA2*‐2 transfection significantly increased apoptotic cells in PANC‐1 cells (Figure [S4](#cas13610-sup-0004){ref-type="supplementary-material"}A‐C).

3.8. Effects of cotransfection of *PHLDA2* and *miR‐148a‐5p* in PDAC cell lines {#cas13610-sec-0022}
-------------------------------------------------------------------------------

To confirm the antitumor effect of *miR‐148a‐5p,* we carried out rescue experiments using *PHLDA2* overexpression in PDAC cells with *miR‐148a‐5p* restoration. Rescue studies indicated that cancer cell migration and invasion properties were rescued by *PHLDA2* transfectants compared with cells with restored *miR‐148a‐5p* only (Figure [7](#cas13610-fig-0007){ref-type="fig"}). These data indicated that *PHLDA2* expression was regulated by *miR‐148a‐5p* and expression of *miR‐148a‐5p* induced antitumor effects on migration and invasion in PDAC cells.

![Rescue experiments: induction of *PHLDA2* overexpression in pancreatic ductal adenocarcinoma (PDAC) cell lines with *miR‐148a‐5p* restoration. A, PHLDA2 protein overexpression in PANC‐1 and SW1990 was evaluated by western blot analyses 72 h after 0.5 μg/well transfection with *PHLDA2* cDNA plasmid (middle bands). PHLDA2 protein overexpression was attenuated 72 h after cotransfection with 0.5 μg/well *PHLDA2* cDNA plasmid and 10 nmol/L *miR‐148a‐5p* mimic (right bands). GAPDH was used as a loading control. B, Cell migration activity was assessed 72 h after cotransfection with 0.5 μg/well *PHLDA2* cDNA plasmid and 10 nmol/L *miR‐148a‐5p* mimic, \**P *\<* *.0001. Cell invasion activity was determined using Matrigel invasion assays 72 h after cotransfection with 0.5 μg/well *PHLDA2* cDNA plasmid and 10 nmol/L *miR‐148a‐5p* mimic, \**P *\<* *.0001](CAS-109-2013-g007){#cas13610-fig-0007}

3.9. Investigation of downstream genes regulated by *PHLDA2* in PDAC cells {#cas13610-sec-0023}
--------------------------------------------------------------------------

Our selection strategy of downstream genes regulated by *PHLDA2* is shown in Figure [8](#cas13610-fig-0008){ref-type="fig"}A. A total of 530 genes was commonly downregulated (log~2~ ratio \< −1.0) in si‐*PHLDA2‐*transfected PANC‐1 cells. We also assessed the upregulated genes in PDAC tissues by GEO database analyses (GEO accession number [GSE15471](GSE15471)). With that approach, we identified 37 genes (Table [5](#cas13610-tbl-0005){ref-type="table-wrap"}). Our microarray expression data were deposited in the GEO database (accession number [GSE106791](GSE106791)).

![Strategy for analysis of *PHLDA2* downstream genes. A, Flow chart illustrates the strategy for analysis of *PHLDA2*‐mediated downstream genes in pancreatic ductal adenocarcinoma (PDAC) cells. B, Kaplan--Meier plots of overall survival with log‐rank tests between those with high and low expression of 12 genes downstream from *PHLDA2* in the PDAC Cancer Genome Atlas (TCGA) database. GEO, Gene Expression Omnibus](CAS-109-2013-g008){#cas13610-fig-0008}

###### 

Downregulated genes by *si‐PHLDA2* transfectants

  Entrez gene ID   Gene symbol   Gene name                                                                             Mock vs si‐PHLDA2_2   GEO      OncoLnc
  ---------------- ------------- ------------------------------------------------------------------------------------- --------------------- -------- -------------
  12               *SERPINA3*    Serpin peptidase inhibitor, clade A (alpha‐1 antiproteinase, antitrypsin), member 3   −2.4052               1.1210   **.0314**
  115207           *KCTD12*      Potassium channel tetramerization domain containing 12                                −1.7676               1.2730   *.0245*
  25924            *MYRIP*       Myosin VIIA and Rab interacting protein                                               −1.7485               1.4215   .099
  8519             *IFITM1*      Interferon induced transmembrane protein 1                                            −1.5832               1.4437   **.0353**
  23621            *BACE1*       Beta‐site APP‐cleaving enzyme 1                                                       −1.5579               1.6490   .31
  6382             *SDC1*        Syndecan 1                                                                            −1.5511               1.3845   **.00787**
  5738             *PTGFRN*      Prostaglandin F2 receptor inhibitor                                                   −1.4976               1.4021   .35
  56605            *ERO1LB*      ERO1‐like beta (S. cerevisiae)                                                        −1.4052               1.6621   No data
  92241            *RCSD1*       RCSD domain containing 1                                                              −1.3758               1.1930   .569
  23075            *SWAP70*      SWAP switching B‐cell complex 70 kDa subunit                                          −1.3742               1.0542   .51
  55612            *FERMT1*      Fermitin family member 1                                                              −1.3590               1.6579   **.00799**
  3613             *IMPA2*       Inositol(myo)‐1(or 4)‐monophosphatase 2                                               −1.3188               1.5101   .615
  57619            *SHROOM3*     Shroom family member 3                                                                −1.3051               1.1286   .132
  2494             *NR5A2*       Nuclear receptor subfamily 5, group A, member 2                                       −1.2469               1.5494   .209
  983              *CDK1*        Cyclin‐dependent kinase 1                                                             −1.2366               1.4143   **.00137**
  54492            *NEURL1B*     Neuralized E3 ubiquitin protein ligase 1B                                             −1.2230               1.2359   .154
  11037            *STON1*       Stonin 1                                                                              −1.2048               1.5983   .654
  10403            *NDC80*       NDC80 kinetochore complex component                                                   −1.1913               1.5473   .126
  253827           *MSRB3*       Methionine sulfoxide reductase B3                                                     −1.1684               1.8859   .902
  4751             *NEK2*        NIMA‐related kinase 2                                                                 −1.1547               1.0279   **.0022**
  25878            *MXRA5*       Matrix‐remodeling associated 5                                                        −1.1433               2.3870   **.0352**
  285590           *SH3PXD2B*    SH3 and PX domains 2B                                                                 −1.1361               1.3111   .848
  84168            *ANTXR1*      Anthrax toxin receptor 1                                                              −1.1311               2.9025   .28
  51316            *PLAC8*       Placenta‐specific 8                                                                   −1.1274               1.6964   .0588
  6241             *RRM2*        Ribonucleotide reductase M2                                                           −1.1057               1.1664   **.00627**
  11130            *ZWINT*       ZW10 interacting kinetochore protein                                                  −1.1000               1.1604   **.000948**
  1728             *NQO1*        NAD(P)H dehydrogenase, quinone 1                                                      −1.0986               2.1867   .61
  54443            *ANLN*        Anillin, actin binding protein                                                        −1.0854               1.7292   **.00142**
  56925            *LXN*         Latexin                                                                               −1.0769               2.0471   .964
  7153             *TOP2A*       Topoisomerase (DNA) II alpha 170 kDa                                                  −1.0455               1.5302   **.0012**
  4085             *MAD2L1*      MAD2 mitotic arrest deficient‐like 1 (yeast)                                          −1.0324               1.1864   .108
  2706             *GJB2*        Gap junction protein, beta 2, 26 kDa                                                  −1.0296               3.6935   **.000459**
  1999             *ELF3*        E74‐like factor 3 (ets domain transcription factor, epithelial‐specific)              −1.0295               1.1854   .174
  9891             *NUAK1*       NUAK family, SNF1‐like kinase, 1                                                      −1.0212               1.6399   .827
  4016             *LOXL1*       Lysyl oxidase‐like 1                                                                  −1.0207               2.3387   .778
  1786             *DNMT1*       DNA (cytosine‐5)‐methyltransferase 1                                                  −1.0184               1.2180   .117
  3223             *HOXC6*       Homeobox C6                                                                           −1.0145               1.9164   .391

Bold values, Kaplan‐Meier analysis log‐rank *P*‐value \<.05, poor prognosis with a high expression.

Italic value, Kaplan‐Meier analysis log‐rank *P*‐value \<.05, poor prognosis with a low expression.

GEO, Gene Expression Omnibus; PDAC, pancreatic ductal adenocarcinoma.

John Wiley & Sons, Ltd

Furthermore, we checked the expression status of those genes and their pathological relations to PDAC by using TCGA‐based large cohort study data. Kaplan‐Meier analysis showed that PDAC patients with high expression of 12 genes (*SERPINA3, IFTM1, SDC1, FERMT1, CDK1, NEK2, MIXRA5, RRM2, ZWINT, ANLN, TOP2A and GJB2*) had significantly poorer overall survival (Figure [8](#cas13610-fig-0008){ref-type="fig"}B).

4. DISCUSSION {#cas13610-sec-0024}
=============

Despite recent developments in treatment, advanced PDAC cannot be cured. Novel approaches for identification of therapeutic targets of PDAC are needed. Based on this, we have identified antitumor miRNAs that regulate cancer pathways in PDAC cells.[26](#cas13610-bib-0026){ref-type="ref"} Our miRNA expression signature of PDAC showed that some passenger strands of miRNAs were significantly downregulated in PDAC.[8](#cas13610-bib-0008){ref-type="ref"} We hypothesize that the data could help to identify miRNAs important for the development and progression of PDAC. In the present study, we focused on pre‐*miR‐148a* strands: *miR‐148a‐5p* (the passenger strand) and *miR‐148a‐3p* (the guide strand). With this focus, we investigated the functional significance of these specific miRNAs and regulatory RNA networks in PDAC cells.

In the human genome, the *miR‐148*‐family consists of 3 members that are located in different chromosomal regions: *miR‐148a* is at 7p15.2, *miR‐148b* is at 12q13.13 and *miR‐152* is at 17q21.32.[27](#cas13610-bib-0027){ref-type="ref"}, [28](#cas13610-bib-0028){ref-type="ref"} The mature sequences of the guide strands of these miRNAs are similar and the seed sequences (UCAGUGCA) are identical.[29](#cas13610-bib-0029){ref-type="ref"} Most analyses have focused on guide strands of the *miR‐148*‐family in normal physiological conditions or in cancer cells.[30](#cas13610-bib-0030){ref-type="ref"}, [31](#cas13610-bib-0031){ref-type="ref"} A large number of previous studies showed that *miR‐148a‐3p* (the guide strand) was downregulated in several types of cancer (eg, gastric cancer, colon cancer, hepatocellular carcinoma, breast cancer and PDAC).[32](#cas13610-bib-0032){ref-type="ref"}, [33](#cas13610-bib-0033){ref-type="ref"}, [34](#cas13610-bib-0034){ref-type="ref"}, [35](#cas13610-bib-0035){ref-type="ref"}, [36](#cas13610-bib-0036){ref-type="ref"} The *miR‐148a* gene contains a large number of CpG islands in the promoter (Figure [S3](#cas13610-sup-0003){ref-type="supplementary-material"}A). In hepatocellular cancer, *miR‐148a* is silenced by DNA hypermethylation.[37](#cas13610-bib-0037){ref-type="ref"} In pancreatic cancer, a past study reported that aberrant hypermethylation of the *miR‐148a* coding region progresses as pancreatic cancer malignancy increases.[38](#cas13610-bib-0038){ref-type="ref"} We showed that hypermethylation suppresses *miR‐148a‐5p* and *miR‐148a‐3p* even in PDAC (Figure [S3](#cas13610-sup-0003){ref-type="supplementary-material"}B). Our present study of *miR‐148a‐3p* is consistent with previous reports. A new finding of the present analysis was that *miR‐148a‐5p* (the passenger strand) acted as an antitumor miRNA as did *miR‐148‐3p* (the guide strand) in PDAC cells. Involvement of the passenger strand of miRNA in cancer pathogenesis is a new concept in the field of miRNA research.

In the present study, we identified oncogenic genes regulated by *miR‐148a‐5p* and *miR‐148a‐3p* in PDAC cells by using genome‐wide gene expression and miRNA database analyses. Three genes (*PHLDA2*,*LPCAT2* and *AP1S3*) were regulated by *miR‐148a‐5p* (passenger strand) and were identified as putative oncogenic genes in PDAC pathogenesis. Similarly, 3 genes (*SAS*,*ENDOD1* and *UHMK1*) were found to be regulated by *miR‐148‐3p* (the guide strand). Analysis of these genes will contribute to the elucidation of the molecular mechanism of PDAC pathogenesis.

We focused on *PHLDA2* and investigated its oncogenic functions because its expression in 2 pancreatic cancer cell lines showed the greatest suppression by *miR‐148a‐5p* (passenger strand). Moreover, the role of *PHLDA2* has been controversial in other carcinomas (ie, its roles as an "oncogene" or "tumor suppressor" are unclear).[39](#cas13610-bib-0039){ref-type="ref"}, [40](#cas13610-bib-0040){ref-type="ref"} Clinical features in TCGA database of PDAC patients showed there were no significant relationships in T, N, and M of TMN stage (data not shown). However, high expression of *PHLDA2* related to poor OS and DFS. Past studies showed that *PHLDA2* acted as a growth‐suppressive gene.[41](#cas13610-bib-0041){ref-type="ref"} *PHLDA2* is located on human chromosome 11p15.5, a location known for imprinting gene clusters.[42](#cas13610-bib-0042){ref-type="ref"} It is well known that dysregulation of this gene cluster is associated with Beckwith‐Wiedemann syndrome.[43](#cas13610-bib-0043){ref-type="ref"} To investigate the functional significance of *PHLDA2*, knockout mice or transgenic mouse studies have been carried out.[44](#cas13610-bib-0044){ref-type="ref"} In *PHLDA2* null mice, placenta overgrowth was observed and overexpression of *PHLDA2* resulted in placental stunting.[45](#cas13610-bib-0045){ref-type="ref"} In humans, upregulation of *PHLDA2* was observed in intrauterine growth restriction placentas.[46](#cas13610-bib-0046){ref-type="ref"} However, the relationship between *PHLDA2* expression and human cancers is not clear.

Our present study showed that *PHLDA2* was overexpressed in PDAC clinical specimens and that its expression enhanced cancer cell migration and invasion in PDAC cells. Moreover, high expression of *PHLDA2* was significantly associated with poor prognosis of PDAC patients based upon a large cohort study. These findings indicate that aberrantly expressed *PHLDA2* acts like a cancer‐promoting gene in PDAC cells. TCGA database analyses indicate that high expression of *PHLDA2* is significantly associated with poor prognoses in several types of cancer (eg, renal cell carcinoma, hepatocellular carcinoma and glioma). Functional analysis will be necessary to verify the cancer‐promoting effects of *PHLDA2*.

Finally, we investigated genes mediated by *PHLDA2* in PDAC cells. Interestingly, past studies showed that aberrant expression of several of the genes (*SDC1*,*CDK1*,*ANLN* and *TOP2A*) contributes to cancer cell aggressiveness.[18](#cas13610-bib-0018){ref-type="ref"}, [47](#cas13610-bib-0047){ref-type="ref"}, [48](#cas13610-bib-0048){ref-type="ref"}, [49](#cas13610-bib-0049){ref-type="ref"} Among these genes, a total of 12 were deeply involved in PDAC pathogenesis by TCGA analyses. Our data suggest that overexpression of *PHLDA2* might induce the expression of downstream cancer‐promoting genes in PDAC cells. These results suggest that *PHLDA2* might be a possible therapeutic target for PDAC patients.

In conclusion, both strands of pre‐*miR‐148a* (*miR‐148a‐5p* and *miR‐148a‐3p*) were significantly reduced in PDAC clinical specimens. The passenger strand, *miR‐148a‐5p*, had a potent antitumor function through targeting of cancer‐promoting genes in PDAC cells. *PHLDA2* was markedly elevated in PDAC, and it was involved in PDAC pathogenesis, suggesting *PHLDA2* could be used as a therapeutic target in PDAC. The involvement of passenger strand miRNAs in the regulation of cellular processes is a novel concept in RNA research.
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